This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

J&J Spent $1.3M Lobbying In 2Q Over Product Issues

Stocks in this article: JNJ MDCO

WASHINGTON (AP) â¿¿ Health products giant Johnson & Johnson spent $1.3 million in the second quarter lobbying on legislation concerning its medicines and consumer health products, many of which have been the subject of repeated recalls over the past two years.

That amount was up slightly from the $1.2 million the New Brunswick, N.J., company spent a year earlier, but down from the $1.7 million it spent in the first quarter.

The maker of Tylenol, Motrin and hip replacements â¿¿ products among the many J&J has recalled around the world â¿¿ lobbied on issues relating to recalls of nonprescription medicines made by its McNeil Consumer Healthcare unit and ingredients in cough and cold medicines that can be abused or used to make the illegal drug methamphetamine.

Since September 2009, J&J has announced an astounding series of more than two dozen recalls of prescription and nonprescription drugs and medical devices. Reasons range from nauseating odors and shards of metal or glass in liquid medicines to the wrong level of active ingredient in some over-the-counter medicines and faulty hip replacements that cause severe pain and require replacement.

The company lobbied on the America Invents Act, the first significant overhaul of patent law since 1952. The legislation, signed into law by President Obama on Sept. 16, is meant to stimulate job creation by streamlining the patent process, reducing costly legal battles and addressing a backlog of about 1.2 million pending patent approvals.

J&J also lobbied on issues related to Food and Drug Administration fees for reviewing and deciding whether to approve new medicines and medical devices, as well as on ensuring the quality of medication ingredients, on rebates paid for drugs purchased through the Medicare program, and for repeal of an excise tax on medical devices.

The company, which makes many popular baby and skin care products, lobbied on regulation of cosmetic products. It also lobbied on tax reform and on a free-trade agreement with Korea.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs